Current Issue

Pharmacy Integration
David B. Nash, MD, MBA
April 2019 Vol 12, No 2 - Editorial
Read More
The Economic Value of Customized Versus Off-the-Shelf Knee Implants in Medicare Fee-for-Service Beneficiaries
Mary I. O’Connor, MD, Brittany E. Blau, MPH
April 2019 Vol 12, No 2 - Business, Original Research
Read More
The Challenge of Managing Atopic Dermatitis in the United States
Steven R. Feldman, MD, PhD, Linda S. Cox, MD, Lindsay C. Strowd, MD, Robert A. Gerber, PharmD, Steven Faulkner, PharmD, MBA, Debra Sierka, PharmD, Timothy W. Smith, BA, Joseph C. Cappelleri, PhD, Mark E. Levenberg, DO
April 2019 Vol 12, No 2 - Clinical
Stakeholder Perspective
Evolving Therapies for Atopic Dermatitis Will Create New Management Challenges
by Gary M. Owens, MD
Read More
Can Academic Detailing Move the Needle for Patients with Diabetes in a State-Based Prescription Drug Benefit Program?
Dominick P. Trombetta, PharmD, BCPS, BCGP, Debra A. Heller, PhD, MPH
April 2019 Vol 12, No 2 - Clinical, Original Research
Read More

Conference Correspondent

Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent - ASH 2018 - Chronic Lymphocytic Leukemia
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent - ASH 2018 - Chronic Lymphocytic Leukemia
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent - ASH 2018 - Chronic Lymphocytic Leukemia

Most Popular Articles

February 1, 2019 - FDA Approvals, News & Updates
Web Exclusives - FDA Approvals, News & Updates, In the News, In the News
Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
Kenneth LaPensee, PhD, MPH, Rohit Mistry, MPharm, MBA, MSc, Thomas Lodise, PharmD, PhD
February 2019, Vol 12, No 1, Supplement 1: Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives - FDA Approvals, News & Updates, In the News

Online First

The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab
Diana Brixner, RPh, PhD, Gary Oderda, PharmD, MPH, Joseph Biskupiak, PhD, MBA, Douglas S. Burgoyne, PharmD, FAMCP, Steven G. Avey, RPh, MS, FAMCP, Steven R. Feldman, MD, PhD
Cost-effectiveness studies of pharmaceutical agents that will soon be released to the market are an important tool that payers and health plans can use when making decisions on coverage, formulary positioning, and budgets.
Read More

Select Drug Updates

Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Copiktra (Duvelisib) Approved for 3 Types of Relapsed or Refractory Leukemia
View All Updates

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?


  • Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME